Prometheus Bio’s IPO raises $190M for inflammatory bowel disease R&D March 12, 2021 Auto Bot BioPharma, biopharma nl, biotech IPO, inflammatory bowel disease, News, Pharma, Precision Medicine, San Diego 0 Prometheus Biosciences is taking a precision medicine approach to developing drugs and diagnostics for inflammatory bowel disease. The IPO cash will fund support its pipeline of IBD drug candidates for specific patient subpopulations.